PCN52 ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX,) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
May 1, 2009, 00:00
10.1016/S1098-3015(10)73289-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)73289-7/fulltext
Title :
PCN52 ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX,) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73289-7&doi=10.1016/S1098-3015(10)73289-7
First page :
Section Title :
Open access? :
No
Section Order :
718